Comparison

GHK-Cu vs “KLOW”:
identity, evidence and legal status

One is a copper-binding peptide with its own research record. The other is a name for a pre-mixed vial that lists it among four peptides. The same questions asked of both, component by component, and no verdict: we found no study of the mix.

Short answerCompound research · 6 min read · Updated 21 Nov 2026

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. KLOW is a seller name for one vial that mixes four peptides, GHK-Cu among them, with BPC-157, TB-500 and KPV. GHK-Cu has its own cell, animal and small human skin studies; we found no published study or registered trial of the KLOW mix (21 November 2026).

Key takeaways

  • GHK-Cu is one molecule, the copper(II) complex of glycyl-L-histidyl-L-lysine; KLOW is a seller name for one vial that lists GHK-Cu, BPC-157, TB-500 and KPV.
  • We found no published study, in any species, and no registered trial that gave the four together, and none comparing the mix with GHK-Cu alone (PubMed and ClinicalTrials.gov, 21 Nov 2026).
  • GHK-Cu’s own record, in the studies cited here, is cell and animal work plus small human skin studies; none of it transfers to a mixed vial.
  • Regulators set status one compound at a time, and none of the status documents we read names the mix.
  • A lab report for a GHK-Cu vial has one identity to confirm; a report for a vial that lists four peptides has four.

01GHK-Cu and KLOW side by side

The same questions, asked of one compound and of a name for a mixed vial. Dated 21 November 2026.

QuestionGHK-CuKLOW
What the name refers toOne molecule: the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysineA seller name for one vial that mixes four peptides
Listed componentsGHK-CuGHK-Cu, BPC-157, TB-500, KPV
Studied under that nameYes: cell, animal and small human skin studiesNo study found, in any species
Compared with the otherNo study foundNo study found
Evidence tier of the studies cited hereOne small randomised skin study in people (T1), plus animal (T3) and cell (T4) studiesGHK-Cu as on the left. BPC-157: small human studies (T2) and animal studies (T3). TB-500: animal and cell studies (T3, T4). KPV: a mouse and cell study (T3, T4)
United StatesDrugs@FDA lists no medicine containing it. FDA’s list of substances nominated for compounding (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, in Category 1, bulk drug substances under evaluation. It is not in HHS’s October 2026 draft policyGHK-Cu as on the left. Drugs@FDA lists no medicine containing BPC-157, TB-500 or KPV. HHS’s October 2026 draft policy, which “is not binding”, names those three and covers single-ingredient products only
AustraliaThe TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own.GHK-Cu as on the left. BPC-157 and TB-500 are in Schedule 4 and Appendix D. For KPV, the TGA statement on the left; we found no entry by name for KPV and draw no scheduling conclusion of our own.
United KingdomThe emc database returned no results for GHK, copper tripeptide or prezatide (21 Nov 2026); it is not the full UK registerThe same for BPC-157, TB-500 and KPV
Sport (WADA 2026 and 2027 Lists)Not named. WADA says a peptide not specifically named “may still be prohibited”GHK-Cu and KPV as on the left. BPC-157 (class S0) and TB-500 (class S2.3) are named, prohibited at all times
Identities a lab report has to confirmOneFour

If you searched “ghk cu vs klow”, the comparison is between one compound and a mixed vial that lists it: what is known about GHK-Cu is not known about the mix. What the name KLOW covers, component by component, and where each component stands: what is the “KLOW peptide”?

02What is the difference between GHK-Cu and KLOW?

One molecule on one side, four listed names on the other. The drawings show which molecules are listed, not how much of each.

Identity

GHK-Cu: one molecule

Glycyl-L-histidyl-L-lysine, a peptide of three amino acids, holding a copper(II) ion. The earliest papers we found on GHK in PubMed date from 1973.

Mix

KLOW: four listed names

GHK-Cu with BPC-157, TB-500 and KPV in one vial. No regulator or peer-reviewed source defines the mix or says how much of each it holds.

Testing

One identity, or four

A report for a GHK-Cu vial has one peptide to identify and measure. A report for a vial listing four has to identify and measure each one.

One purity percentage for a vial that lists four peptides cannot show that each one is present, or how much of each there is. Evidence attaches to what was studied, never to a name for a mix: peptide blends: one vial, no shared evidence.

03What has GHK-Cu been studied in, and does any of it cover the mix?

GHK-Cu’s own record, design and measures only. None of these studies gave GHK-Cu with another peptide.

StudyModel and nWhat was measuredTier
Miller et al., 2006People: a randomised comparison of skin-care regimens with or without GHK-Cu after laser resurfacing around the mouth; 13 completedRedness, by software and blinded evaluators; wrinkles and skin quality at 12 weeks; a patient questionnaireT1, small
Maquart et al., 1993Rats with implanted wound chambers; n not given in the abstractDry weight, protein, collagen and DNA content of the chamber tissueT3
Maquart et al., 1988Fibroblasts in cultureCollagen production by the cellsT4

The 2006 trial is the one randomised study in people that we cite here; it is small, and it measured skin after a laser procedure. An animal or cell result is not evidence of an effect in people, and material sold online is not the product these studies tested. GHK-Cu’s guide grades its human evidence “Early human”: the GHK-Cu guide.

What GHK-Cu’s record says about the mix. Nothing. On 21 November 2026 we searched PubMed with the component names, quoted and unquoted: no paper names all four. Eight papers name GHK-Cu together with BPC-157, and each is a review, commentary or letter; the one that names KPV beside GHK-Cu is a review. No PubMed record uses KLOW as the name of a peptide mix, and ClinicalTrials.gov lists no trial that gives two or more of the four together.

04Where do GHK-Cu and the other three components stand with regulators and in sport?

Component by component. None of the status documents we read names the mix.

  1. Sep 2023FDA Category 2

    BPC-157, TB-500 and KPV enter FDA’s list of compounding substances that may present significant safety risks.

  2. 22 Apr 2026Out of Category 2

    HHS records that neither the placement nor the removal changed the status of the three under section 503A.

  3. 14 May 2026GHK-Cu under evaluation

    FDA’s updated list places GHK-Cu, for certain routes of administration only, in Category 1. FDA says it intends to consult its compounding advisory committee before the end of February 2027.

  4. 23–24 Jul 2026Advisory committee meets

    FDA staff propose not adding BPC-157, TB-500 or KPV to the 503A bulks list. HHS records that the committee voted in favour of each. GHK-Cu was not on the agenda.

  5. 1 Oct 2026Poisons Standard October 2026 in force

    Australia’s current standard lists BPC-157 and TB-500 in Schedule 4 and Appendix D. We found no entry by name for GHK-Cu or KPV.

  6. 30 Oct 2026HHS draft policy published

    It names six peptides, including BPC-157, TB-500 and KPV, not GHK-Cu, and applies only when a product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. The notice calls it a draft that “is not binding”.

  7. 1 Jan 2027WADA 2027 List takes effect

    BPC-157 (class S0) and TB-500 (class S2.3) remain named. GHK-Cu and KPV are not named, and WADA says a peptide not specifically named “may still be prohibited”.

In the UK, the emc database of licensed-medicine information returned no results for any of the four names on 21 November 2026; it is not the full UK register. GHK-Cu’s US record, with its dates: is GHK-Cu legal in the US? Each KLOW component, country by country: the KLOW page. Sport: peptides and anti-doping.

05What we don’t know, and how to check a vial

There is no evidence to rank the single compound against the mix. These are the open questions, and the one check anyone can run.

1
Whether GHK-Cu research applies to the mix

We found no study that gave GHK-Cu together with BPC-157, TB-500 or KPV, in any species (PubMed and ClinicalTrials.gov, 21 Nov 2026).

2
Whether four peptides stay intact together

Whether they stay stable in one vial, or change one another, is a separate question. We found no published data.

3
Whether the mix differs from GHK-Cu alone

That needs the same model and measures, with a group for GHK-Cu alone and a group for the mix. We found none, published or registered.

4
What a given vial holds

Only that lot’s lab report can show it: one identity for a GHK-Cu vial, four identities and four amounts for a vial that lists four peptides.

How to read those lines on a report: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.

RefSources

  1. Pickart L, Margolina A. [Review of GHK-Cu research.] Int J Mol Sci, 2018;19(7):1987. PMID 29986520; identity section read 21 Nov 2026. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  2. Pickart L, Thaler MM. [Report of a tripeptide in human serum, tested on liver cells in culture.] Nat New Biol, 1973;243(124):85–87. PMID 4349963; PubMed record (no abstract) read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/4349963/
  3. Miller TR, Wagner JD, Baack BR, Eisbach KJ. [Randomised skin-care comparison after laser resurfacing.] Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/16847171/
  4. Maquart FX, Bellon G, Chaqour B, et al. [Connective-tissue measurements in a rat wound-chamber model.] J Clin Invest, 1993;92(5):2368–2376. PMID 8227353; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/8227353/
  5. Maquart FX, Pickart L, Laurent M, et al. [Collagen measurements in fibroblast cultures.] FEBS Lett, 1988;238(2):343–346. PMID 3169264; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/3169264/
  6. PubMed searches (title and abstract; names quoted and unquoted): all four components together, 0 results; (GHK OR GHK-Cu OR copper tripeptide OR prezatide) AND (BPC OR BPC-157 OR BPC157 OR pentadecapeptide OR bepecin), 8 results, each a review, commentary or letter; with TB-500 or thymosin beta names added, 7; KPV with GHK names, 1 (a review); KLOW with “peptide”, 0. Database searches, 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28GHK%5Btiab%5D+OR+%22copper+…
  7. ClinicalTrials.gov. Intervention searches for GHK-Cu (4 records), copper tripeptide-1 (2), BPC-157 names (4), TB-500 (1) and KPV and KLOW (0): no record gives two or more of the four. Registry searches through API v2, 21 Nov 2026. clinicaltrials.gov/search?intr=GHK-Cu
  8. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3), including the GHK-Cu update. List updated 14 May 2026; downloaded and read 21 Nov 2026. www.fda.gov/media/94155/download
  9. U.S. Food and Drug Administration. Drugs@FDA data through the openFDA API (data last updated 20 Nov 2026): no product matches GHK, prezatide, BPC-157, thymosin or KPV as an active ingredient (control search, somatropin: 12 records). Database queries, 21 Nov 2026. api.fda.gov/drug/drugsfda.json?limit=1
  10. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, Oct 2026; read 21 Nov 2026 on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov returned 403 to our tools). web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  11. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026; text read on govinfo 21 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.ht…
  12. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327): Schedule 4 and Appendix D, clause 5. Federal Register of Legislation, registered 30 Sep 2026, commenced 1 Oct 2026; as-made text searched 21 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  13. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read 21 Nov 2026 on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  14. World Anti-Doping Agency. Prohibited List 2027 (in force 1 Jan 2027), classes S0 and S2.3, read beside the 2026 List, and the 2027 summary of major modifications and explanatory notes (undated in its text). International Standard; PDFs downloaded 21 Nov 2026 (SHA-1 8e84d248… and 08b06d5a…) and searched. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  15. Electronic medicines compendium (emc). Searches for GHK, copper tripeptide, KPV, BPC-157 and TB-500: “No search results” for each (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=GHK

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

What is the difference between GHK-Cu and KLOW?

GHK-Cu is one peptide, the copper(II) complex of glycyl-L-histidyl-L-lysine. KLOW is a seller name for a vial that lists GHK-Cu with three other peptides: BPC-157, TB-500 and KPV.

Has any study compared GHK-Cu with KLOW?

Not that we found (PubMed and ClinicalTrials.gov, 21 Nov 2026). We found no study of the KLOW mix on its own either, so there is nothing to compare.

Does research on GHK-Cu cover the KLOW mix?

No. Evidence attaches to what was studied, and none of the GHK-Cu studies cited here gave it together with BPC-157, TB-500 or KPV.

Are GHK-Cu and the other KLOW components named on WADA’s Prohibited List?

BPC-157 (class S0) and TB-500 (class S2.3) are named as prohibited at all times. GHK-Cu and KPV are not named, and WADA says a peptide not specifically named “may still be prohibited”.

How many identities does a lab report have to confirm?

One for a GHK-Cu vial. For a vial that lists four peptides, four: each one identified and measured on its own.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page